Life Science Nation Newsletter  |  April 24, 2014  |  Issue 59

LSN Videos
LSN Investor Database Demo
Life Science Investor Mandates
CVC of Tech Giant
Angel Group 
Recent News

Quick Links
Schedule a Database Demo

The Importance of Single-Asset Focus  
By Maximilian Klietmann, VP of Marketing, LSN

LSN regularly speaks with numerous early stage entrepreneurs on the subject of asset focus. All too frequently, scientist entrepreneurs are reluctant to choose a single asset for the focus of their company unwilling to believe that it is in their best interest. Despite the feedback LSN gets from ongoing conversations with life science investors, many emerging biotech entrepreneurs still see this as a debatable point.


The typical arguments that emerging life science CEOs make against a single-asset focus may appear to make sense at first: Investors should prefer multiple shots on the goal or a portfolio of products is worth more than the sum of its parts. However, the key point that is often missed is that multiple assets frequently spell increased risk from an investor's perspective. Why is this? It can be boiled down to three basic factors.

VC Strategies Diverge in the Valley of Death 
By Lucy Parkinson, Research Manager, LSN


We've talked about the fact that many venture capital firms have withdrawn from investing in early stage biotech startups, contributing to the so-called "Valley of Death." However, there are still a number of life science VCs that remain active, so what are they doing with their dry powder now and why?


Talking to VCs recently, we found that the bulk of these funds are diverging in two directions. Some VCs are looking for nascent technological breakthroughs that are, generally, still a long way from becoming biotech startup companies. These VCs are building companies around these breakthroughs, gaining access to new scientific works either by maintaining a network of leading academics or by performing initial research entirely in-house...



FDA Proposes Expedited Access Program for Medical Devices 

By Michael Quigley, Research Manager, LSN


Earlier this week, the FDA announced a new program that intended to provide earlier access to unapproved medical devices for certain patientsThe EAP (Expedited Access Premarket Approval Application) program will allow companies to directly engage with the FDA sooner to collaboratively develop a plan for collecting scientific and clinical data in order to get patients safer and more effective devices sooner. The basic objective of the program is to diagnose and treat patients who are suffering from serious conditions and have medical needs that are unmet by current 


So, which companies are allowed to apply for the program? According to the FDA...

Address: 9B Hamilton Place, Boston, MA, 02108, USA

Phone: +1 (617) 600-0668


follow us: Follow us on Twitter View our profile on LinkedIn